In major news, Sanofi has been the subject of positive interest in the bio-tech sphere. Despite safety concerns and mixed results, their eczema drug continues to generate interest. However, uncertainty arose as German CDMO Adragos purchased a French sterile injectables plant from Sanofi. Amidst these changes, the company also returned to T-cell engager territory with a massive $1.2B pact while also making headway in skin disease treatments in collaboration with Incyte, Roivant, and Alumis. In a surprising move, the firm made a potential $1B deal with Kali Therapeutics for the development of autoimmune treatment. The company further bolstered their reputation when it was revealed that Texas was suing Sanofi over alleged 'bribing' of providers to boost drug prescriptions. However, the firm also faced challenges as the new CEO, Belén Garijo, navigates the Trump presidency and the price of Sanofi dropped after the announcement of Paul Hudson's replacement. Finally, the company announced its plan to expand to India which could increase the workforce to over 4,500 employees.
Sanofi News Analytics from Fri, 06 Jun 2025 07:00:00 GMT to Sat, 04 Apr 2026 22:36:48 GMT -
Rating -1
- Innovation 4
- Information 6
- Rumor 7
